News

Analysts covering United States Antimony have adjusted their price targets, with one bullish research note moving from US$9 to US$11, while the modelled fair value remains at US$12.67 per share. That shift is tied closely to optimism around the planned hydrometallurgical facility at the Galena Complex, potential federal funding, and progress across the wider project pipeline. As you read on, you will see what is driving these views and how to track the evolving narrative around the...

United States Antimony’s latest analyst update keeps the model fair value anchored at US$12.67 per share, with no change to the central price target. That steady figure sits against mixed views, where more optimistic analysts connect their confidence to progress at the Galena Complex and planned federal funding. More cautious voices, however, point to execution, permitting, and funding risks across multiple projects. As you read on, you will see how these moving parts shape the evolving story...